Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112957 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
A Phase 2 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00112957 is a Phase 2 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 23 participants.
The verdict
NCT00112957, a Phase 2 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This was a Phase 2, single-center, open-label study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) injections in patients who had a complete response to standard therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and whose tumors expressed NY-ESO-1 or LAGE-1 antigen. Study objectives were to evaluate maintenance of remission at 12 months, time to failure of vaccine therapy, cellular and humoral immunity and any correlation with time to failure, and safety.
Interventions
- BIOLOGICAL rV-NY-ESO-1 vaccine
- BIOLOGICAL rF-NY-ESO-1 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-12 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00112957
The ClinicalTrials.gov registry entry for NCT00112957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rV-NY-ESO-1 vaccine is the first listed.
NCT00112957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00112957 about?
NCT00112957 is a clinical study titled "Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer". This was a Phase 2, single-center, open-label study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) injections in patients who had a complete response to standard therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma and whose t...
What is the current status of trial NCT00112957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-12. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00112957?
The interventions under investigation include: rV-NY-ESO-1 vaccine (BIOLOGICAL), rF-NY-ESO-1 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00112957?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.